Ignite Creation Date:
2024-05-06 @ 3:51 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04787445
Status:
COMPLETED
Last Update Posted:
2024-03-21
First Post:
2021-02-15
Brief Title:
Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension An Exercise Hemodynamic Study TAPH Study
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to characterize the clinical and hemodynamic response of Pulmonary Arterial Hypertension PAH therapy in patients with atypical PAH and risk factors for left heart disease
Detailed Description:
This is an observational prospective study to better understand the clinical impact of Pulmonary Arterial Hypertension PAH specific therapy in patients with atypical PAH among those with risk factors for left heart disease
The study involves detailed baseline clinical evaluation prior to initiation of PAH therapy followed by repeat clinical assessment after 6 months of medical therapy
The study involves detailed baseline clinical evaluation prior to initiation of PAH therapy followed by repeat clinical assessment after 6 months of medical therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None